To the Editor: Court, Bergh and Södersten raise the issue of why and how some therapies with prima facie evidence for their efficacy have a significant take-up by medical practitioners, while others are allowed to languish, sometimes for decades.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- Phillip Gray
- Queanbeyan, NSW.
Correspondence: gray.qbn@effect.net.au
Online responses are no longer available. Please refer to our instructions for authors page for more information.